The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 29, 2020
Filed:
Jul. 27, 2017
Applicant:
Mitobridge, Inc., Cambridge, MA (US);
Inventors:
Eric Bell, Somerville, MA (US);
Nan Ji, Arlington, MA (US);
Dominique Stickens, Boston, MA (US);
Taisuke Takahashi, Tsukuba, JP;
Effie Tozzo, Lexington, MA (US);
Assignee:
Mitobridge, Inc., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/416 (2006.01); A61K 31/166 (2006.01); A61K 31/351 (2006.01); A61K 31/353 (2006.01); A61K 31/381 (2006.01); A61K 31/4184 (2006.01); A61P 13/12 (2006.01); A61K 33/243 (2019.01); A61K 9/00 (2006.01); A61K 31/454 (2006.01); A61K 31/502 (2006.01); A61K 31/5025 (2006.01); A61K 31/546 (2006.01); A61K 31/55 (2006.01); A61K 31/7048 (2006.01); A61K 38/13 (2006.01); A61K 31/5517 (2006.01); A61K 31/63 (2006.01); A61K 31/473 (2006.01); A61K 31/5377 (2006.01); A61K 31/519 (2006.01); A61K 31/496 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/416 (2013.01); A61K 9/0019 (2013.01); A61K 31/166 (2013.01); A61K 31/351 (2013.01); A61K 31/353 (2013.01); A61K 31/381 (2013.01); A61K 31/4184 (2013.01); A61K 31/454 (2013.01); A61K 31/473 (2013.01); A61K 31/496 (2013.01); A61K 31/502 (2013.01); A61K 31/5025 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/546 (2013.01); A61K 31/55 (2013.01); A61K 31/5517 (2013.01); A61K 31/63 (2013.01); A61K 31/7048 (2013.01); A61K 33/243 (2019.01); A61K 38/13 (2013.01); A61P 13/12 (2018.01); A61K 45/06 (2013.01);
Abstract
The present invention also contemplates a method of treating a human patient with acute kidney injury or reducing the likelihood of developing acute kidney injury in a human patient at risk of developing acute kidney injury comprising administering to the patient a poly-ADP ribose polymerase (PARP) inhibitor in a therapeutically effective dose so as to thereby treat the patient.